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Abstract
Aims/hypothesis Adiponectin is an adipokine with insulin-
sensitising and anti-atherogenic properties. Several reports
suggest that genetic variants in the adiponectin gene are
associated with circulating levels of adiponectin, insulin
sensitivity and type 2 diabetes risk. Recently two receptors
for adiponectin have been cloned. Genetic studies have
yielded conflicting results on the role of these genes and
type 2 diabetes predisposition. In this study we aimed to
evaluate the potential role of genetic variation in these
genes in syndromes of severe insulin resistance, type 2
diabetes and in related metabolic traits in UK Europid
populations.
Materials and methods Exons and splice junctions of the
adiponectin receptor 1 and 2 genes (ADIPOR1; ADIPOR2)
were sequenced in patients from our severe insulin
resistance cohort (n=129). Subsequently, 24 polymorphisms
were tested for association with type 2 diabetes in
population-based type 2 diabetes case–control studies
(n=2,127) and with quantitative traits in a population-based
longitudinal study (n=1,721).
Results No missense or nonsense mutations in ADIPOR1
and ADIPOR2 were detected in the cohort of patients with
severe insulin resistance. None of the 24 polymorphisms
(allele frequency 2.3–48.3%) tested was associated with
type 2 diabetes in the case–control study. Similarly, none of
the polymorphisms was associated with fasting plasma
insulin, fasting and 2-h post-load plasma glucose, 30-min
insulin increment or BMI.
Conclusions/interpretation Genetic variation in ADIPOR1
and ADIPOR2 is not a major cause of extreme insulin
resistance in humans, nor does it contribute in a significant
manner to type 2 diabetes risk and related traits in UK
Europid populations.
Keywords ADIPOR1.ADIPOR2.Associationstudies.
Insulin resistance.Polymorphisms.Type2diabetes
Abbreviations
ADIPOR1 adiponectin receptor 1
ADIPOR2 adiponectin receptor 2
LD linkage disequilibrium
SIR severe insulin resistance (cohort)
SNP single nucleotide polymorphism
Introduction
Adiponectin, encoded by the gene ADIPOQ (also
known as 30-kDa adipocyte complement-related protein,
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protein-28 or GBP28), is an adipokine with insulin-
sensitising [1, 2] and anti-atherogenic actions [3]. Its
levels correlate strongly with insulin sensitivity in humans
and animal models, and increasing levels of plasma
adiponectin produce a sensitising effect to the biological
action of insulin [4]. Several genetic reports have detected
association between adiponectin gene variants and obesity,
insulin resistance, type 2 diabetes, and adiponectin levels
[5–9].
Recently, two adiponectin receptors were identified,
adiponectin receptor 1 (ADIPOR1), cloned from a human
skeletal muscle expression library, and adiponectin receptor
2( ADIPOR2), identified using computational tools by
Yamauchi et al. [10]. In mice, Adipor1 is expressed
ubiquitously, with higher levels in skeletal muscle, and
has a higher affinity for the globular form of adiponectin.
Adipor2, on the other hand, is most abundant in the liver
and preferentially binds the full-length form of adiponectin
[10]. In contrast, both human ADIPOR1 (375aa) and
ADIPOR2 (311aa) were predominantly expressed in skel-
etal muscle [10, 11].
In Mexican Americans, glucose-tolerant individuals
with a family history of type 2 diabetes were reported to
exhibit significantly lower levels of mRNA for ADIPOR1
and ADIPOR2 in skeletal muscle than subjects without a
family history of diabetes. mRNA levels of both receptors
were also reported to positively correlate with glucose
disposal [11]. It is possible therefore that lower expression
or altered function of the receptors would predispose to
increased insulin resistance and type 2 diabetes. In fact,
common variants in the ADIPOR1 gene were recently
tested for association in a case–control study with white
and African American individuals, but no association was
reported [12]. Two additional studies have evaluated the
role of adiponectin receptor variants and risk of type 2
diabetes. In the Old Order Amish population, two intronic
variants in ADIPOR1 were reported to associate with risk
of type 2 diabetes, while in ADIPOR2 an extended
haplotype block was associated with increased risk of
disease [13]. In contrast, in a Japanese population no
associations between polymorphisms in adiponectin re-
ceptor genes and risk of type 2 diabetes were detected
[14]. More recently, studies in French and Finnish
populations reported no association between ADIPOR1
single nucleotide polymorphisms (SNPs) and type 2
diabetes [15, 16], although evidence for association
between rs767870 in ADIPOR2 and type 2 diabetes in a
French population has been suggested [15]. In light of
these studies, and the potential role of these receptors in
insulin action and diabetes, we sought to identify and
investigate the effects of genetic variants in these genes in
UK populations.
Subjects and methods
Participants
Severe insulin resistance cohort A cohort of human
patients with severe insulin resistance (SIR cohort) was
collected at the University of Cambridge, UK. The
inclusion criteria for this cohort were: (1) fasting insulin
>150 pmol/l or exogenous insulin requirement >200 U/day;
(2) acanthosis nigricans; and (3) BMI <33 kg/m
2. In the
present study, 129 patients from this cohort were screened
for mutations in exons and splice junctions of ADIPOR1
and ADIPOR2 genes. Cambridge Local Research Ethics
Committee approval was obtained, and informed consent
was received from all individuals before participation.
Cambridgeshire Case–Control Study The Cambridgeshire
Case–Control Study has been described previously [17].
Briefly, this population-based case–control study consists of
552 type 2 diabetes patients and matched control subjects.
DNA was available from 516 cases and control subjects for
this study. The cases were a random sample of Europid men
and women with type 2 diabetes, aged 47 to 75 years, from
a population-based diabetes register in a geographically
defined region in Cambridgeshire, UK. The presence of
type 2 diabetes in these participants was defined as onset of
diabetes after the age of 30 years without use of insulin
therapy in the first year after diagnosis. The control
participants were individually matched to each of the
diabetic subjects by age, sex and geographical location,
but not by BMI. Potential control subjects with HbA1c
levels greater than 6% were excluded, as this subgroup
could have contained a higher proportion of individuals
with previously undiagnosed diabetes. Ethical approval for
the study was granted by the Cambridge Local Research
Ethics Committee.
EPIC-Norfolk participants This is a nested case–control
study within the EPIC-Norfolk prospective cohort study;
both the case–control and full cohort study [18, 19] have
been described in detail previously. Briefly, the case–control
study consists of 417 incident type 2 diabetes cases and two
sets of 417 control subjects, matched on age, sex, time in
study and family physician, with the second set additionally
matched for BMI. A case was defined by a physician’s
diagnosis of type 2 diabetes, with no insulin prescribed
within the first year after diagnosis, and/or HbA1c >7% at
baseline or the follow-up health check. Controls were
selected from those in the cohort who had not reported
diabetes, cancer, stroke or myocardial infarction at baseline,
and who had not developed diabetes by the time of
selection. Potential control subjects with measured HbA1c
levels >6% were excluded. DNA was available for this
556 Diabetologia (2007) 50:555–562analysis from 354 cases and 741 control subjects. Ethical
approval for the study was granted by the Norwich Local
Research Ethics Committee.
Ely Study This is a population-based cohort study of the
aetiology and pathogenesis of type 2 diabetes and related
metabolic disorders in the UK [20]. It uses an ethnically
homogeneous Europid population, in which phenotypic data
were recorded at the outset and after 4.5 years. The cohort
was recruited from a population sampling frame with a high
response rate (74%), making it representative of the general
population for this area in Eastern England. This analysis
included 1,721 men and women, aged 35–79 years and
without diagnosed diabetes, who attended the study clinic for
a health check between 2000 and 2004. Of these, 1,005 were
attending a follow-up health check, while the remaining 716
were newly recruited in 2000 from the original population
sampling frame. Participants attending the health check
underwent standard anthropometric measurements and a
75-g oral glucose tolerance test. Plasma glucose was
measured using the hexokinase method. Plasma insulin was
measured by two-site immunometric assays with either
125I
or alkaline phosphatase labels. Cross-reactivity with intact
proinsulin was less than 0.2% and interassay CVs were less
than 7%. Ethical approval for the study was granted by the
Cambridge Local Research Ethics Committee.
PCR and sequencing
Genomic DNA from patients was randomly preamplified in
a GenomiPhi reaction (GE Healthcare UK, Chalfont St.
Giles, UK) prior to amplification with gene-specific
primers. Primers were designed using Primer3 software
[21] to cover all coding exons and splice junctions. PCR
primers and expected product sizes are described in
Electronic supplementary material (ESM) Table 1. Follow-
ing PCR, performed using standard conditions, products
were purified using exonuclease I and shrimp alkaline
phosphatase (USB Corporation, Cleveland, OH, USA), and
bi-directional sequencing was performed using a DNA
sequencing kit (Big Dye Terminator 3.1; Applied Biosys-
tems, Foster City, CA, USA). Sequencing reactions were
run on ABI3700 capillary machines (Applied Biosystems)
and sequences were analysed using Mutation Surveyor
version.2.20 (SoftGenetics LLC, State College, PA, USA).
Genotyping
SNP selection AllSNPswithaminorallelefrequencygreater
than 2% in our SIR cohort were selected for genotyping. To
increase coverage in areas not re-sequenced, a number of
dbSNPs were selected in an attempt to eliminate gaps,
betweengenotypedSNPs,ofgreaterthan2.5–3kbonav er ag e
(additional SNPs were selected prior to HapMap phase I data
release). SNP choice was based on the following criteria: (1)
all putative non-synonymous SNPs in dbSNP were selected
irrespective of whether or not there was frequency or
validation information for the SNP; (2) SNPs with frequency
information were selected if their minor allele frequency was
greater than or equal to 5%; (3) for SNPs with no frequency
information the choice was based on whether the SNP was a
double-hit SNP, had been validated by-cluster or by-sub-
mitter; and finally (4) some SNPs with no validation
information were included to try and eliminate gaps of greater
than 2.5–3 kb between SNPs selected for genotyping.
Genotyping and quality control Samples were arrayed on
96-well plates with three replicates and one water control
per plate. For the case–control populations, cases and
control samples were randomly distributed across each 96-
well plate, with approximately the same number of cases
and controls per plate. Genotyping of samples was
performed in 384-well plates at the Wellcome Trust Sanger
Institute, Cambridge, using an adaptation of the homoge-
nous MassExtend protocol for the MassArray system
(Sequenom, San Diego, CA, USA) [22]. Assay results for
case–control are described in ESM Table 2. The following
criteria were used to pass assays resulting from genotyping:
(1) call rates had to be greater than or equal to 90% (in one
case a call rate of 88% was accepted); (2) concordance rates
between duplicate samples had to be greater than or equal
to 98%; (3) minor allele frequency had to be greater than or
equal to 1% in the genotyped populations; (4) agreement
with Hardy–Weinberg equilibrium was tested separately in
cases and controls using a χ2 goodness-of-fit test, and if
p<0.01 in controls, the assay was failed, while if p<0.01 in
cases, the assay was flagged but included in primary
analysis. Assays that failed quality control were excluded
from further analysis. In total we analysed results from nine
SNPs in ADIPOR1 and 15 SNPs from ADIPOR2.
Statistical analysis
All analyses used SAS 8.02 (SAS Institute, Cary, NC,
USA) or Stata 7.0 (Stata Corporation, College Station, TX,
USA) statistical programs, unless otherwise stated. All used
genotypes were in Hardy–Weinberg equilibrium. The pair-
wise linkage disequilibrium (LD) coefficient for the con-
trols (r
2) was calculated for genotyped SNPs and is
represented in Fig. 1. For each SNP, two primary models
were used to assess association with diabetes and quanti-
tative traits, the linear trend (additive model) on 1df and the
general model on 2df. Since the results from these analyses
were not materially different, we present only the results
Diabetologia (2007) 50:555–562 557558 Diabetologia (2007) 50:555–562from the linear trend test. Tests for association were
performed by logistic regression combined in the two
case–control populations adjusting for age, sex and popu-
lation. Between-study heterogeneity was tested by log-
likelihood ratio tests. Quantitative trait analysis was
undertaken in the Ely Study population. Association
between fasting plasma insulin, fasting and 2-h post-load
plasma glucose, 30-min insulin increment (30-min insulin
minus fasting insulin over 30-min glucose in an OGTT),
BMI and genotype was tested in a multiple regression
model, adjusted for age and sex.
Results
To evaluate whether genetic variation in ADIPOR1 and
ADIPOR2 contributed to severe insulin resistance in
humans, we sequenced exons and splice junctions in both
genes in 129 individuals from our SIR cohort. These
individuals were unrelated and had a variety of syndromes
of severe insulin resistance [23]. We identified 13 and 29
polymorphisms in ADIPOR1 and ADIPOR2 respectively,
none of which altered the protein sequence of either gene
(ESM Table 3). This suggests that no functional mutations
were identified in these genes. We next tested whether
c o m m o nv a r i a n t sa tt h e s eg e n e si m p a c t e do nt y p e2
diabetes predisposition or related quantitative traits in UK
Europid populations. We selected all variants with a minor
allele frequency greater than 2% in the SIR cohort and
supplemented our SNP selection with additional variants
from the dbSNP database plus SNPs with significant
association results in other published studies. Thirteen
polymorphisms from ADIPOR1 and 23 polymorphisms
from ADIPOR2 were selected for genotyping in two type 2
diabetes case–control studies (n=2,127) and one metabolic
quantitative trait study (n=1,721) (Fig. 1). Those SNPs that
passed our genotyping quality control criteria (described in
methods) were used to investigate the degree of LD in
control individuals across ADIPOR1 and ADIPOR2. In total
nine SNPs in ADIPOR1 and 15 SNPs in ADIPOR2 were
included in the analysis. LD was measured by r
2 statistic
and is depicted in Fig. 1. Under both general and linear
trend models no evidence was found for statistically
significant associations between SNPs and disease risk
(Table 1). In ADIPOR1, SNPs rs2275738, rs2275735 and
rs10581 were removed from the quantitative trait analysis as
they were out of Hardy–Weinberg equilibrium (p<0.01). For
the remaining SNPs there was also no evidence for asso-
ciation of the SNPs tested with BMI, fasting and 2-h glucose
levels, fasting insulin or 30-min insulin incremental response
(ESM Table 4). In ADIPOR2 a few SNPs showed nominally
significant association with BMI and 2-h glucose levels.
However, these results are likely to be chance findings given
the number of statistical tests performed (ESM Table 4).
Discussion
The current study, including sequencing of 129 patients
with syndromes of severe insulin resistance and genotyping
of both population-based type 2 diabetes case–control
studies (n=2,127) and a metabolic quantitative trait study
(n=1,721), suggests that ADIPOR1 and ADIPOR2 genetic
variants are unlikely to be major risk factors for type 2
diabetes and insulin resistance in UK Europid populations.
Although sequencing of ADIPOR1 and ADIPOR2 genes
in a cohort of patients with syndromes of severe insulin
resistance (n=129) led to the identification of 42 poly-
morphisms, including 21 novel rare variants, none altered
the protein sequence. Given that this group of patients
comprises a heterogeneous cohort representative of a variety
of syndromes of extreme insulin resistance, the lack of
variants affecting the protein sequence suggests that func-
tional mutations in the genes ADIPOR1 and ADIPOR2 are
not major causes of extreme insulin resistance in humans.
For ADIPOR1, our data in case–control studies are
consistent with previous reports showing that SNPs in this
gene are not associated with type 2 diabetes risk in Europid
[12, 15, 16], African [12] or Japanese populations [14].
This is in contrast to evidence from the Old Order Amish,
where an association of rs2275738 (and rs2275737 which is
in perfect LD with it) and rs1342387 with type 2 diabetes
risk has been reported [13]. Since the Amish represent an
isolated population, it is possible that variants in ADIPOR1
play a role in type 2 diabetes predisposition among them,
which is not apparent in more heterogeneous populations.
However, given that both reported associated SNPs are
present in all populations, it is unlikely that either is the true
causal variant, although they could be detecting, through
LD, the effect of an untested SNP. Alternatively, given the
relative small sample sizes used and lack of adjustment for
multiple testing, the authors may have reported a false–
positive association.
For ADIPOR2 the data are less consistent. While no
evidence of association between ADIPOR2 SNPs and type
2 diabetes was present in a Japanese population [14], an
association has been suggested between SNP rs767870 and
type 2 diabetes risk in French populations [15]. Our data,
Fig. 1 Genomic structure and pair-wise marker LD in ADIPOR1 (a)
and ADIPOR2 (b). The location of SNPs identified in this study and/or
genotyped is represented along the gene (bold type: SNPs selected for
genotyping, and failed or monomorphic SNPs). Exons are represented
in boxes (black for coding and open for untranslated). Introns and
flanking sequences appear as lines. The pair-wise marker LD
measured by r2 statistics is shown below the genomic structures and
indicated by the shade of grey blocks (white to black) and the r2 value.
a, b, isoforms a and b in ADIPOR2
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560 Diabetologia (2007) 50:555–562and those from the Old Order Amish [13], do not support
this finding. Notably, in the French population, meta-
analysis of rs767870, including 1,380 individuals with type
2 diabetes and 1,496 controls, demonstrated allelic associ-
ation of nominal significance only (p=0.02), while the most
significant result was under a recessive model (p=0.0018).
Our study has only 23% power to detect such small
recessive effects (odds ratio 1.3) with an allele frequency
of 0.15, and this could explain our discrepant result. Further
large scale studies of this SNP in additional populations
will be required to elucidate its role in conferring risk of
disease. A haplotype was also reported to increase risk of
diabetes in the Old Order Amish [13]. However, when we
performed haplotype analyses in both ADIPOR1 and
ADIPOR2, we were unable to detect any significant
associations with diabetes risk (data not shown), and this
discrepancy might also be accounted for by differences in
the populations studied.
With regard to quantitative metabolic traits, to date
two studies have reported nominally significant results
with insulin sensitivity and body size [16, 24]. The first
study showed nominally significant associations between
two tightly linked SNPs (rs6666089 and an intronic –1927
SNP) in ADIPOR1 and decreased insulin sensitivity and
increased HbA1c levels [24]. We did not test association
with HbA1c, but have not replicated any association with
insulin sensitivity (including with SNP rs6666089)
as assessed by fasting insulin measurements. Recently
Kantartzis and colleagues reported that the association
between rs6666089 and insulin sensitivity is observed only
in more obese, but not in lean individuals [25]. This
dependence on the degree of adiposity could explain some
of the discrepant results observed for this SNP, if there are
substantial differences in mean BMI between populations
tested. To explore this hypothesis, we performed
SNP×BMI interaction tests (using BMI both as a contin-
uous trait and splitting the population above and below the
median) on all ADIPOR1 SNPs tested. Our data provided
no evidence for such an interaction (data not shown). We
also specifically tested for association between rs6666089,
and measures of insulin and glucose in participants with
BMI above and below 25. Again we found no statistically
significant difference between the two groups (p>0.3).
Therefore, it is unlikely that BMI differences between
populations are at the root of our discrepant results. Of
note, our data cannot exclude possible small effects of this
SNP on insulin sensitivity, in particular if this effect is only
observed in subjects with higher BMI. The second study
suggested there was evidence of association between two
markers (rs10920534 and rs2275738) and BMI, but this
evidence came from men only. Furthermore, three other
markers (rs10920534, rs12045862 and rs7539542) were
r e p o r t e dt oa s s o c i a t ew i t hf a s t i n ga n d2 - hi n s u l i nl e v e l s ,
particularly in men at baseline [16]. We did not test
rs10920534, but did test rs6666089 (D′=r
2=1 with
rs10920534) and found no evidence for SNP×sex interaction
on any of the quantitative traits we analysed. Our data also
did not replicate the sex effect of SNP rs7539542 on insulin
measurements. Although we did not test SNP rs12045862,
previously published data was conflicting. Thus while the C
allele was suggested to be associated with higher 2-h insulin
levels in men (p=0.027), in women the T allele was
associated with higher levels (p=0.029) [16]. Given that
neither we, nor others [24], have found evidence for
sex×SNP interaction effects on measures of insulin sensitiv-
ity, we suggest that further confirmatory studies are required
to test this hypothesis.
Until recently, remaining uncertainty regarding the
identity of the true physiological receptors for adiponectin
[26] had hampered interpretation of the functional rele-
vance of polymorphisms in ADIPOR1 and ADIPOR2 with
respect to adiponectin’s insulin sensitising effects. Howev-
er, a recent yeast two-hybrid screen identified an ADIPOR1
interacting molecule, APPL1, thought to mediate many of
the effects of adiponectin [27]. This molecule was shown to
interact with both ADIPOR1 and ADIPOR2 in an adipo-
nectin-sensitive manner, and was shown to mediate many
of adiponectin’s insulin-sensitising effects. This suggests
that ADIPOR1 and ADIPOR2 could be therapeutic targets
for drug development and should renew interest in
association studies, such as those we present here, testing
polymorphisms in ADIPOR1 and ADIPOR2 for effects on
type 2 diabetes risk and metabolic traits.
In summary, sequencing of ADIPOR1 and ADIPOR2
genes in a cohort of patients with syndromes of severe
insulin resistance (n=129) suggests that functional muta-
tions in these genes are not a major cause of extreme insulin
resistance in humans. Furthermore, testing of common
genetic variants (n=24) did not find evidence for associa-
tion of these genes with type 2 diabetes risk (n=2,127) or
with five additional quantitative metabolic traits (n=1,721).
These data suggest that ADIPOR1 and ADIPOR2 variants
are unlikely to be major risk factors for type 2 diabetes and
insulin resistance in UK Europid populations, although
more detailed analyses of gene variants may be required to
exclude a potential minor role of these genes in insulin
resistance and glucose homeostasis.
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